Dioseve Expands Funding to Enhance ReproNest Product Development

Dioseve, a biotech company leveraging its unique differentiation induction technology to efficiently generate oocytes and ovarian somatic cells from iPS cells, has successfully raised ¥1 billion in a Series A extension round. This round, announced on June 15, 2026, was led by Archetype Ventures with participation from DG Daiwa Ventures, Miraidoor (Asuka Innovation Fund), D4V, Shionogi & Co., Ltd., and Pangaea Ventures.

Focus on In Vitro Maturation

Dioseve is focused on developing co-culture type in vitro maturation (IVM) products, specifically targeting the maturation of immature oocytes using ovarian support cell-like cells derived from iPS cells. Their flagship product, "ReproNest" (development code DIOS-101), aims to improve the efficiency of IVM by co-culturing patient-derived oocytes with support cells in a shared environment, thereby reducing the burden on patients undergoing in vitro fertilization.

Strategic Use of Funds

The newly acquired capital will be directed towards several key initiatives:

  • Validation and Practical Application: The funds will support the validation process for ReproNest, ensuring its practical application in clinical settings.
  • Manufacturing and Quality Control: Dioseve plans to establish robust manufacturing and quality control systems to ensure product reliability and compliance with regulatory standards.
  • Business Development: The company aims to enhance its business development efforts both domestically and internationally to expand its market presence.

Investors and Industry Impact

Archetype Ventures spearheaded this funding round, with substantial support from DG Daiwa Ventures and Miraidoor, among others. The involvement of these investors highlights the growing interest in biotechnology solutions that utilize iPS cells for reproductive health.

Dioseve's innovative approach holds promise for future applications, including fertility preservation and rapid fertility preservation before cancer treatment. The company also plans to leverage the NEDO Deep Tech Startup Support Program (DTSU) to further these advancements.

With this funding, Dioseve is well-positioned to advance its technology and potentially transform the landscape of reproductive biotechnology.